Article Details

JPM 2024: Codagenix CEO Paul Grint on its COVID-19 and RSV Vaccine Development

Retrieved on: 2024-01-09 14:17:45

Tags for this article:

Click the tags to see associated articles and topics

JPM 2024: Codagenix CEO Paul Grint on its COVID-19 and RSV Vaccine Development. View article details on hiswai:

Excerpt

Grint said that Codagenix uses synthetic biology to change the codons in a viral genome, which “revs up” the replication process and essentially ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up